Nanjing Leads Biolabs Co Ltd (9887.HK) Comparison with companies in other sectors?

Nanjing Leads Biolabs Co Ltd has a share price of 198.89M. You can analyze Nanjing Leads Biolabs Co Ltd (9887.HK) competitors across different market sectors through stock heatmaps.

What are 9887.HK's NET and operating margins?

Nanjing Leads Biolabs Co Ltd (9887.HK) operating margin is around N/A, and net profit margin is approximately N/A as of the latest reports.

In what way does 9887.HK's earnings per share (EPS) trend reflect its financial momentum?

Nanjing Leads Biolabs Co Ltd (9887.HK) EPS is -1.37 (If EPS value is positive, then "signals consistent profit growth" if Negative then "signals consistent loss"). This metric is also critical in assessing valuation metrics like the P/E ratio for Nanjing Leads Biolabs Co Ltd is -64.23, and the company's ability to reinvest or distribute profits.

What does a high ROE mean for Nanjing Leads Biolabs Co Ltd?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Nanjing Leads Biolabs Co Ltd like P/E which is N/A, P/B which is N/A, and PEG which is N/A. Compare them with sector averages to evaluate if the stock is priced fairly.

Nanjing Leads Biolabs Co Ltd

9887.HK•HKSE

Healthcare

Biotechnology

HK$93.15

HK$19.15(25.88%)

Hong Kong Market is Open • 11:44

Nanjing Leads Biolabs Co Ltd Fundamental Analysis

Nanjing Leads Biolabs Co Ltd (9887.HK) shows weak financial fundamentals with a PE ratio of -64.23, profit margin of N/A, and ROE of N/A. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

No significant strengths identified.

Areas of Concern

No major concerns flagged.

We analyze 9887.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 0.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

0.0/100

We analyze 9887.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

9887.HK struggles to generate sufficient returns from assets.

ROA > 10%

N/A

Valuation Score

Moderate

9887.HK shows balanced valuation metrics.

PE < 25

-64.23

PEG Ratio < 2

N/A

Growth Score

Weak

9887.HK faces weak or negative growth trends.

Revenue Growth > 5%

N/A

EPS Growth > 10%

N/A

Financial Health Score

Weak

9887.HK carries high financial risk with limited liquidity.

Debt/Equity < 1

N/A

Current Ratio > 1

N/A

Profitability Score

Weak

9887.HK struggles to sustain strong margins.

ROE > 15%

N/A

Net Margin ≥ 15%

N/A

Positive Free Cash Flow

N/A

Key Financial Metrics

Is 9887.HK Expensive or Cheap?

P/E Ratio

9887.HK trades at -64.23 times earnings. This suggests potential undervaluation.

-64.23

How Well Does 9887.HK Make Money?

No data available.

Following the Money - Real Cash Generation

No data available.

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

N/A

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

N/A

vs 25 benchmark

P/B Ratio

Price to book value ratio

N/A

vs 25 benchmark

P/S Ratio

Price to sales ratio

N/A

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

N/A

vs 25 benchmark

Current Ratio

Current assets to current liabilities

N/A

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

N/A

vs 25 benchmark

ROA

Return on assets percentage

N/A

vs 25 benchmark

ROCE

Return on capital employed

N/A

vs 25 benchmark

How 9887.HK Stacks Against Its Sector Peers

Metric	9887.HK Value	Sector Average	Performance
P/E Ratio	N/A	28.31	N/A
ROE	N/A	699.00%	N/A
Net Margin	N/A	-130884.00% (disorted)	N/A
Debt/Equity	N/A	0.34	N/A
Current Ratio	N/A	2775.16	N/A
ROA	N/A	-14469.00% (disorted)	N/A

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Nanjing Leads Biolabs Co Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Nanjing Leads Biolabs Co Ltd Fundamental Analysis

Key Strengths

Areas of Concern

Fundamental Health Score

Efficiency Score

Valuation Score

Growth Score

Financial Health Score

Profitability Score

Key Financial Metrics

Is 9887.HK Expensive or Cheap?

How Well Does 9887.HK Make Money?

Following the Money - Real Cash Generation

Financial Ratios Analysis

Valuation Ratios

Financial Health

Efficiency Ratios

How 9887.HK Stacks Against Its Sector Peers

Historical Growth Performance

5-Year Growth Trajectory

Fundamental Analysis FAQ

Nanjing Leads Biolabs Co Ltd (9887.HK) Comparison with companies in other sectors?

What are 9887.HK's NET and operating margins?

In what way does 9887.HK's earnings per share (EPS) trend reflect its financial momentum?

What does a high ROE mean for Nanjing Leads Biolabs Co Ltd?

How do I know if AAPL is overvalued or undervalued?